Drug Profile
GLY 230
Alternative Names: EXO-230; GLY-230Latest Information Update: 02 Aug 2016
Price :
$50
*
At a glance
- Originator Exocell
- Developer Glycadia
- Class Small molecules
- Mechanism of Action Glycosylation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Alzheimer's disease; Diabetic nephropathies; Diabetic retinopathy
Most Recent Events
- 07 Feb 2011 No development reported - Phase-I/II for Diabetic nephropathies in USA (PO)
- 07 Feb 2011 No development reported - Preclinical for Alzheimer's disease in USA (PO)
- 30 Apr 2009 Preclinical trials in Alzheimer's disease in USA (PO)